BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
Merck
Biopharmaceutical company
Company Info
Recent News
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
Merck's anti-TL1A secures a ph. 2 hidradenitis suppurativa win
Merck's anti-TL1A secures a ph. 2 hidradenitis suppurativa win
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda's patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.
MSD, Daiichi pull filing for lung cancer candidate I-DXd
MSD and Daiichi Sankyo's regulatory efforts for their ADCs for cancer have stuttered again, with a withdrawn filing for lung cancer candidate I-DXd.
Merck, Eisai's Welireg-Lenvima combo lands FDA nod to jump the kidney cancer queue
The FDA approved Merck's HIF-2 alpha inhibitor Welireg in combination with Eisai-partnered Lenvima for second-line clear cell renal cell carcinoma following a PD-(L)1 inhibitor, lifting the drug beyond its original third-line use.
Wnt drug gives MSD first eye disease win after EyeBio deal
MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.
Merck's experimental eye drug matches Roche's VEGF inhibitor but safety concerns emerge
Merck's experimental ophthalmology drug matched Roche's VEGF inhibitor in a late-stage study, though safety concerns emerged.
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to bre
Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch
Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
How the Merck/Moderna cancer vaccine works and possible barriers to wide use, includes gallery
How the Merck/Moderna cancer vaccine works and possible barriers to wide use, includes gallery
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
Merck-Moderna vaccine data spur talk of Keytruda-like impact
Merck-Moderna vaccine data spur talk of Keytruda-like impact
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
Merck and Sarah Cannon team up for oncology trial efficiency
Merck and Sarah Cannon team up for oncology trial efficiency
Merck and Sarah Cannon team up for oncology trial efficiency
Merck and Sarah Cannon team up for oncology trial efficiency
Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma
Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma
New study supports testing of Merck's Ebola vaccine in DRC outbreak
New study supports expanded testing of Merck's Ebola vaccine in response to the ongoing DRC outbreak.
Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria
Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria — Endpoints News coverage of biopharma industry developments.
Merck halts ph. 2 Alzheimer’s trial after underwhelming efficacy
Merck halts ph. 2 Alzheimer’s trial after underwhelming efficacy — Fierce Biotech coverage of biopharma industry developments.